PVLA News and Press, Palvella Therapeutics Inc. From 02/24/26

2026-02-24 16:21:59 ET More on Palvella Therapeutics Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst Palvella surges on late-stage trial win for lead asset Adagene, Palvella gain after FDA Fast Track Designations Seeking Alpha’s Quant Rat...

2026-02-24 16:10:01 ET Denver, Colorado - Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to oncology platforms and hyperscale compute, today’s developments are sha...

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malfo...

WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin dis...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second h...

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA ® , povorcitinib, ILUMYA®, ODOMZO ® , REMICADE ® , and STELARA ® Dr. Patel to lead Palvella’s M...

2026-01-06 11:59:13 ET More on the markets Jubilant Hopes For The U.S. Stock Market For 2026 U.S. Economy Expected To Cool In Q4, Based On Latest Nowcasts Housing Looks Like A Low-Risk Opportunity Now U.S. stocks continue climbing thanks to Nvidia, tech trade...

2025-12-23 10:43:39 ET ... Read the full article on Seeking Alpha For further details see: Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

2025-12-16 09:24:19 ET More on Adagene, Palvella Therapeutics Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM Seeking Alpha’s Quant Rating on Adagene ADR Historical earnings data for Adagene ADR Financial information for Adagene ADR ...

Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN™ rapamycin for angiokeratomas may be eligible for Accelerated Approval and Priority Review in the ...